olema.com Open in urlscan Pro
35.224.55.107  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to content

Toggle navigation
Home

About

Science
 * Publications


Pipeline

Patients

Investors & Media

Careers
 * Culture


Contact


 * Privacy Policy
 * Terms of Use

 * 
 * 
   




OUR GOALS ARE BIG. OUR MISSION IS POWERFUL.


OUR GOALS ARE BIG. OUR MISSION IS POWERFUL.


OUR GOALS ARE BIG. OUR MISSION IS POWERFUL.


OUR GOALS ARE BIG. OUR MISSION IS POWERFUL.

 1. 
 2. 
 3. 
 4. 

button/interactions/pause circle@2x


CHALLENGING OURSELVES TO IMPROVE THE LIVES OF OTHERS

We exist to develop therapies that offer the potential to improve outcomes for
women living with cancer. We approach these goals with a single-minded focus.

At Olema Oncology, we leverage our deep understanding of endocrine-driven
cancers, nuclear receptors, and mechanisms of acquired resistance, to achieve
our goal of transforming the standard of care for women living with cancer by
focusing on developing more convenient and effective therapies.

Join us as we aim to design therapies for improving lives.

About Olema


LATEST NEWS



For more information, visit the Investors & Media section of our website.

See All News
Open in a new tab
September 6th, 2022 Olema Oncology to Present at H.C. Wainwright 24th Annual
Global Investment Conference
Open in a new tab
September 1st, 2022 Olema Oncology Reports Inducement Grants Under Nasdaq
Listing Rule 5635(c)(4)
Open in a new tab
August 9th, 2022 Olema Oncology Reports Second Quarter 2022 Financial Results
and Provides Corporate Update

For more information, visit the Investors & Media section of our website.

See All News


OUR NOVEL APPROACH TO ADVANCING BREAST CANCER THERAPY

Many forms and stages of cancer continue to elude control. Malignant cells adapt
and exploit mutations and redundancies, so partial targeting leaves
vulnerabilities. 

At Olema, we have no patience for incomplete efforts, so we’re developing
OP-1250, an orally bioavailable Complete Estrogen Receptor Antagonist, or CERAN,
and selective ER degrader, or SERD, for the treatment of ER-positive (ER+),
human epidermal growth factor receptor 2-negative (HER2-) metastatic breast
cancer.

Our Pipeline


LIFE AT OLEMA

I was inspired to join Olema by the enthusiasm of the founding team both for the
impact they are hoping to make on treatment for ER+ breast cancer and the
science driving their research. I believe Olema has a chance to make a real
difference improving the treatment options for women with breast cancer and I’m
excited to be a part of their journey.

— Alison Parisian Scientist at Olema Oncology
Careers


Onto something bigger, together.

Join Us

San Francisco

512 2nd St., 4th Floor

San Francisco, CA 94107

Cambridge

245 Main Street, 4th Floor

Cambridge, MA 02142

Contact

info@olema.com

 * 
 * 
   

 * ©2022 Olema Oncology. Olema, Olema Oncology and our logo are trademarks of
   Olema Oncology.    All rights reserved.

 * Privacy Policy
 * Terms of Use

This site uses cookies to offer you a better browsing experience. Find out more
on how we use cookies and how you can change your settings in our Privacy &
Cookie Policy.

Accept